Modified Clostridial toxins with altered targeting capabilities for Clostridial toxin target cells

Details for Australian Patent Application No. 2006225116 (hide)

Owner Allergan, Inc.

Inventors Fernandez-Salas, Ester; Gilmore, Marcella A.; Li, Shengwen; Francis, Joseph; Aoki, Kei R.; Steward, Lance E.

Agent Davies Collison Cave

Pub. Number AU-B-2006225116

PCT Pub. Number WO2006/099590

Priority 60/661,953 15.03.05 US; 60/662,151 15.03.05 US

Filing date 14 March 2006

Wipo publication date 21 September 2006

Acceptance publication date 19 April 2012

International Classifications

C07K 14/33 (2006.01) Peptides having more than 20 amino acids

Event Publications

1 November 2007 PCT application entered the National Phase

  PCT publication WO2006/099590 Priority application(s): WO2006/099590

19 April 2012 Application Accepted

  Published as AU-B-2006225116

16 August 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006225117-Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations

2006225115-Threedimensional motion capture